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How Do Antidepressants Work? Minireview
Prospects for Genetic Analysis
of Drug Mechanisms
and are consistent with most experimental data (Leo-
nard, 1994; Potter, 1996). However, a number of facts
are difficult to reconcile with the serotonin model, at
least in its simplest form. For example, if levels of sero-
tonergic transmission were directly correlated with
William R. Schafer
Department of Biology
University of California, San Diego
La Jolla, California 92093-0349
mood, one might predict that normal individuals treated
with serotonin reuptake blockers would experience eu-
Fluoxetine and the Serotonin Model for Depression phoria, and that dietary serotonin depletion would in-
Fluoxetine (a.k.a. Prozac) is well known for its ability to duce depression. In fact, these manipulations of seroto-
treat clinical depression, one of the most prevalent of nin levels have little effect on mood except in individuals
all psychiatric disorders. Yet the mechanism by which who are depressed or recently recovered from depres-
fluoxetine actually functions to relieve depression is not sion (McAllister-Williams and Young, 1998). Moreover,
well understood. Fluoxetine is the best-known member even in depressed patients the effects of serotonin reup-
of a class of antidepressant drugs known as serotonin- take blockers on mood do not correlate temporally with
selective reuptake inhibitors (SSRIs). In popular ac- their effects on serotonergic transmission; whereas
counts, their antidepressant action is usually explained SSRIs and most tricyclics elevate synaptic serotonin
in the context of a long-standing model of depression levels within hours, their effects on mood are not appar-
called the serotonin hypothesis. According to this ent for 2±6 weeks. Finally, although many drugs used
model, levels of serotonergic neurotransmission in the to treat mood disorders block uptake or degradation of
forebrain are a key determinant of mood: high activity serotonin, a number of effective antidepressants clearly
results in euphoria, low activity results in dysphoria. do not, including selective norepinephrine reuptake in-
Depression is said to be caused by chronically low levels hibitors (SNRIs) such as desipramine and atypical anti-
of serotonergic transmission. SSRIs interfere with the depressants such as tianeptine, which enhances rather
activity of the serotonin transporter (5-HTT), a reuptake than inhibits serotonin reuptake, MK869, which antago-
molecule that removes serotonin from the synapse; nizes substance P receptors, and bupropion, whose tar-
thus, the putative low levels of synaptic serotonin in get is unknown (Baldessarini, 1996; Kramer et al., 1998).
the depressed patient are elevated, and depression is Together, these observations indicate that any con-
relieved. Consistent with this model, many other antide- nection between serotonin and mood is likely to be more
pressants, including tricyclics (e.g., clomipramine) and complicated and perhaps more indirect than a simplistic
monoamine oxidase inhibitors, also potentiate seroto- version of the serotonin model would imply. Conse-
nergic transmission by interfering with serotonin reup- quently, most current versions of the serotonin model
take or degradation. hypothesize that SSRIs are effective against depression
Variations on this serotonin model represent the most not because of their acute effects on serotonergic trans-
mission, but because of long-term adaptive changes inwidely accepted explanation for antidepressant action
Figure 1. Models for How Chemically Diverse




monoamine neurotransmission that arise from chronic since cellular signaling pathways are often highly con-
inhibition of serotonin reuptake (Leonard, 1994). Ac- served across evolution, the information gained from
cording to this hypothesis (Figure 1A), long-term activa- studying simple organisms is likely to provide critical
tion of different direct targets by different classes of insights into how the same process works in more com-
antidepressants (the serotonin transporter by SSRIs, plex organisms. In this case, they decided to study fluox-
other targets by atypical antidepressants) leads to a etine responses in a simple, experimentally accessible
common set of adaptive responses that include changes organism, the nematode C. elegans, with the notion that
in the sensitivity or expression of various monoamine human homologs of these molecules might be relevant
and GABA receptors in the brain. However, it is also to the clinical activities of antidepressants. Although this
possible that the antidepressant properties of fluoxetine paper represents only a first step in these investigations,
and other antidepressants might be mediated, at least it clearly demonstrates the enormous potential that ge-
in part, by common, serotonin-independent targets (Fig- netic analysis offers as a way to investigate the molecu-
ure 1B). lar basis for drug responses. And though it may be too
The identification of possible serotonin-independent soon to know whether this sort of pharmacological ge-
targets of fluoxetine (and other antidepressants) could netics will ultimately provide an explanation of how anti-
be important for another reason. The major advantage depressants work in humans, past history (along with
of SSRIs over older antidepressant drugs is their relative some encouraging news from the worm genome) sug-
lack of adverse side effects. Even so, patients taking gests that the prospects are quite good.
fluoxetine often experience nausea, headaches, motor Choy and Thomas first demonstrated that fluoxetine
agitation, sleep disorders, and sexual dysfunction (Bal- has serotonin-independent as well as serotonin-depen-
dessarini, 1996). Thus, it is obviously of great interest dent effects on worm behavior. Exposure to fluoxetine
to identify new antidepressant drugs that are more po- has two major effects on worms: stimulation of egg
tent and specific in their alleviation of depression, yet laying and hypercontraction of muscles in the nose.
cause fewer side effects. At present, however, it is not Previous work had indicated that the effect of fluoxetine
clear which side effects are a consequence of serotonin- on egg laying was probably due to potentiation of sero-
reuptake inhibition and which are due to the action of tonergic transmission (Weinshenker et al., 1995). This
the drug at other potential targets. It is known that cyto- conclusion rests on the observations (1) that serotonin,
chrome P450 isoenzymes in the liver, which are impor- like fluoxetine, stimulates egg laying , and (2) that mutant
tant for excretion of many drugs, are directly inhibited by animals that can not synthesize endogenous serotonin
fluoxetine, and the adverse interactions between SSRIs fail to lay eggs in response to fluoxetine. Thus, the rele-
and other drugs may result in part from these serotonin- vant molecular target for fluoxetine with respect to egg
independent actions of fluoxetine (Ereshefsky et al., laying is most likely the serotonin transporter. In con-
1996). It is conceivable therefore that serotonin-inde- trast, the effect of fluoxetine on the nose muscles ap-
pendent targets in the nervous system might underlie pears to be completely independent of serotonin. Even
some of its behavioral and neurological side effects as high serotonin concentrations do not cause nose con-
well. traction, and the ability of fluoxetine to induce nose
Thus, both the antidepressant activity and the adverse contraction is unaffected by mutations that block sero-
side effects of fluoxetine could, at least in principle, tonin synthesis. Remarkably, treatment with other anti-
involve serotonin-independent target molecules. Yet be- depressant drugs, including the chemically unrelated
cause it is difficult to guess what these molecules might tricyclic antidepressant clomipramine, induced contrac-
be, few attempts have been made to identify 5-HTT- tion of the nose muscles in a manner indistinguishable
independent targets of fluoxetine, or even to determine from fluoxetine. Thus, the ability to contract the nose
if they exist. In a way, the problem is reminiscent of muscles represents a common, serotonin-independent
the situation faced by the proverbial inebriate who only
property of multiple antidepressant drugs and suggests
searches for his lost keys under the streetlight because
that these agents might share common serotonin-inde-
the light is better there. In this case, investigations of
pendent molecular targets.fluoxetine's mechanism of action have been limited by
Next, Choy and Thomas screened for mutant animalsthe assumption that the only important target of fluoxe-
that were resistant to fluoxetine-induced nose contrac-tine with respect to depression is the serotonin trans-
tion. They identified fluoxetine resistant mutations inporter. Of course, this might very well be true. However,
seven genes, which they designated Nrf genes, for noseif the antidepressant mechanism of fluoxetine in fact
resistant to fluoxetine. Since all the Nrf mutations wereinvolves alternative, serotonin-independent target mole-
recessive, the seven genes identified in this initial screencules, their identification will be essential for under-
appear to be good candidates for mediating the seroto-standing how antidepressants work. Yet given the ab-
nin-independent effects of fluoxetine. Particularly en-sence of a convincing animal model for depression, it
couraging is the fact that all the Nrf mutations conferhas been difficult to devise a strategy to identify such
resistance to several chemically diverse molecules thattargets.
share the ability to alleviate depression. Nonetheless,Fluoxetine Resistance Genes in C. elegans
the Nrf mutants retain sensitivity to other drugs, suchIn a paper published in the August issue of Molecular
as nicotinic agonists, that can also induce nose contrac-Cell, Choy and Thomas describe a novel approach they
tion. It therefore appears unlikely that the Nrf geneshave used to identify serotonin-independent targets of
prevent fluoxetine-induced nose contraction in a non-fluoxetine and other antidepressants (Choy and Thomas,
specific way, such as by crippling the contractile activity1999). This study applies to pharmacology a time-hon-
ored principle of molecular and developmental biology: of the nose muscles. Thus, the Nrf genes appear to
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encode a set of functionally related molecules that medi- of drugs, even if they are novel or unsuspected. It seems
ate the response of the nose muscles to fluoxetine and certain that the Nrf screen will be an effective way to
other antidepressants. identify additional molecules that mediate serotonin-
How Do NRF-6 and NDG-4 Promote independent responses to fluoxetine in C. elegans, and
Fluoxetine Response? given the facility of nematode genetics, it is probably
The ultimate elucidation of the molecular basis for the only a matter of time before these responses are under-
fluoxetine response of the nose muscles will require the stood at the molecular level.
cloning and molecular characterization of the Nrf genes. However, a skeptic might ask whether understanding
So far two of the Nrf genes have been cloned, nrf-6 and how fluoxetine makes a worm's nose contract will pro-
ndg-4. These two genes define the first members of a vide meaningful insight into how it alleviates mood disor-
novel gene family, and thus the biochemical activities ders in humans. Of course, it is possible that the mole-
of their gene products are not yet known. Both encode cules involved in fluoxetine-induced nose contraction
predicted multipass integral membrane proteins that are will have no direct connection to the clinical mecha-
expressed not in the nose muscle themselves, but in nisms of antidepressants; this question can not be re-
the nasal epidermis. Given their expression patterns and solved definitively until human Nrf gene homologs are
putative structure, perhaps the most logical explanation identified and characterized. However, the nearly com-
of their role in fluoxetine response is that they might plete C. elegans genome sequence indicates that many
transport the drug across the nasal epidermis, where it (though not all) molecules involved in neurotransmission
could access the nasal neuromusculature. Consistent
and neuronal excitability are conserved between nema-
with this hypothesis, other aspects of the nrf-6 and
todes and vertebrates (Bargmann, 1998), several ofndg-4 mutant phenotype strongly suggest defects in the
which have been first identified in C. elegans (Culotti,transport of molecules across cellular boundaries. In
1994; Rand and Nonet, 1997). It should also be notednrf-6 or ndg-4 mutants yolk proteins, which are normally
that recent genetic studies of lithium response pathwaystransported from the intestine to the gonad across a
in Dictyostelium, an organism which diverged from thebarrier of nrf-6/ndg-4-expressing cells, accumulate in
human line far earlier than nematodes, have identifiedthe gut, suggesting that the NRF-6 and NDG-4 proteins
genes previously linked to bipolar depression (Williamsfacilitate transport of yolk proteins across the intestine.
et al., 1999). Thus, it is reasonable to expect that atIf NRF-6 and NDG-4 do in fact function as fluoxetine
the molecular level, fluoxetine response pathways mighttransport molecules, the NRF-6 and NDG-4 vertebrate
show similarly impressive conservation.homologs might not represent fluoxetine targets per se,
Prospects for Genetic Analysis of Otherbut might rather function in transport of antidepressants
Drug Mechanismsacross the blood±brain barrier.
A more specific question regarding the Nrf screen isHowever, if NRF-6/NDG-4 function in drug transport,
whether the serotonin-independent fluoxetine targetsit is curious that such a transporter would specifically
defined by the Nrf mutants will be the ones most relevanttransport multiple structurally dissimilar antidepressant
to understanding depression.molecules. Thus, an alternative possibility must be con-
Since the Nrf screen assayed relatively rapid paralysissidered: that despite their localized expression in the
nasal epidermis, NRF-6 and NDG-4 might actually en- by toxic concentrations of fluoxetine, genes specifically
code targets of fluoxetine. In a simple version of this required for the long-term adaptive pathways would
hypothesis, activation of NRF-6/NDG-4 by fluoxetine probably not be identified by the Nrf screen. However,
could promote the release of factors from epidermal the adaptive downregulation of egg-laying behavior
cells that induce nose muscle contraction. In fact, the after that prolonged exposure to serotonin (Schafer and
nematode nasal epidermis is known to contain acetyl- Kenyon, 1995) might be used as a basis for a genetic
choline, a neurotransmitter implicated in excitation of screen to identify genes involved in long-term serotonin-
the nose muscles (Johnson and Stretton, 1985). How- dependent responses to fluoxetine. Alternatively, since
ever, compelling evidence for involvement of acetylcho- the C. elegans genome sequence is nearly complete,
line or other epidermally released factors in the response the entire genome could be comprehensively surveyed
to fluoxetine is currently lacking. At present, the data using DNA microarrays to identify genes that are in-
are insufficient to distinguish between these and other duced or repressed by prolonged exposure to fluoxetine
models for how NRF-6 and NDG-4 promote fluoxetine-
(DeRisi et al., 1997). Of course, eventually this approach
induced nose contraction; the resolution of this question
can be used to identify fluoxetine-regulated humanprobably awaits the cloning and molecular analysis of
genes as well.the remaining Nrf genes.
Essentially all of the techniques described here couldWill Mutant Worms Help Us
be applied equally well to other neuroactive substancesUnderstand Depression?
that affect humans and worms (or flies) in a conservedThis study clearly demonstrates that in nematodes, flu-
fashion. For example, the mechanisms of action of ther-oxetine has effects on the neuromuscular system that
apeutic agents such as antipsychotics and anaestheticsare mediated by serotonin-independent target mole-
(Kayser et al., 1999; van Swinderen et al., 1999) maycules. Although it is not clear if similar target molecules
ultimately be understood in part through genetic studiesare present in humans, the existence of expressed se-
of resistant or hypersensitive mutants. Likewise, manyquence homologs of nrf-6/ndg-4 indicates that their
drugs of abuse have dramatic effects on worm and flyfunction is not restricted to nematodes. This study also
behavior (McClung and Hirsch, 1998; Moore et al., 1998);effectively illustrates the power of using a phenotypically
based genetic screen to identify the molecular targets genetic analysis of the long-term responses to these
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agents may provide important insights into the mecha-
nisms of addiction. Drugs have historically been effec-
tive tools for investigating how worm neurons work;
worm neurons may prove equally effective for investigat-
ing how drugs work.
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